Article metrics
PDF
Other content recommended for you
- Autoantibody testing in idiopathic inflammatory myopathies
- Evaluation and treatment of inflammatory myopathies
- SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies
- Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort
- Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups
- Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies
- Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy
- The EuroMyositis registry: an international collaborative tool to facilitate myositis research
- Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies
- Proximal myopathy: diagnostic approach and initial management